Human Pathology
Volume 41, Issue 5 , Pages 663-671, May 2010

Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases

  • Marlo M. Nicolas, MD

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
  • ,
  • Pheroze Tamboli, MD

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
  • ,
  • Jose A. Gomez, MD

      Affiliations

    • Department of Pathology, London Health Sciences Centre, University Hospital, London, ON N6A 5A5, Canada
  • ,
  • Bogdan A. Czerniak, MD, PhD

      Affiliations

    • Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    • Corresponding Author InformationCorresponding author.

Received 14 May 2009; received in revised form 1 October 2009; accepted 8 October 2009. published online 11 December 2009.

Summary 

In this article, we supplement the few published articles by describing the clinical and pathologic features of pleomorphic and dedifferentiated leiomyosarcoma from 41 patients (27 women and 14 men) with an age range of 25 to 75 years (mean, 56.5 years), representing the largest cohort reported to date. The typical leiomyosarcoma component accounted for <5% to 60% (mean, 15%) of the tumor. The pleomorphic sarcoma component was composed of polygonal cells in 57% of cases, spindle cells in 21%, a combination of polygonal, epithelioid, rhabdoid, and/or spindle cells in 18%, and predominantly epithelioid cells in 3%. The classical leiomyosarcoma component was positive for at least one myogenic immunohistochemical marker in 29 tumors tested; smooth muscle actin in 100% (27/27), calponin in 90% (9/10), muscle-specific actin in 90% (10/11), desmin in 86% (23/27), smooth muscle myosin heavy chain (SMMS-1) in 67% (4/6), and caldesmon in 57% (4/7). The pleomorphic sarcoma component was reactive for at least one muscle marker in 77% (23/30) of cases; smooth muscle actin in 63% (17/27), calponin in 60% (6/10), SMMS-1 in 60% (3/5), desmin in 59% (16/27), muscle-specific actin in 40% (4/10), and caldesmon in 29% (2/7). The classical leiomyosarcoma component was often strongly positive for myogenic markers, and the pleomorphic sarcoma component usually showed focal and less intense immunoreactivity. Based on staining for muscle markers in the pleomorphic component, twenty-three cases were designated as pleomorphic leiomyosarcoma, and 7 cases were designated as dedifferentiated leiomyosarcoma (negative for all muscle markers used). Eleven cases, in which tissue was not available for immunhistochemical stains, the question of pleomorphic versus dedifferentiated leiomyosarcoma could not be answered. The incidence of metastasis was 89% (32/36) and the mortality rate was 50% (18/36) at last follow-up (3-104 months; mean, 27.5 months).

Keywords: Pleomorphic, Dedifferentiated, Leiomyosarcoma, Immunohistochemical, Retroperitoneum

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0046-8177(09)00370-0

doi:10.1016/j.humpath.2009.10.005

Human Pathology
Volume 41, Issue 5 , Pages 663-671, May 2010